For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Research and development | - | 23,380 | ||
| Total revenues | 294,282 | 179,278 | ||
| Cost of product sales | 19,621 | 18,647 | ||
| Research and development | 33,295 | - | ||
| Selling, general and administrative | 115,900 | 113,059 | ||
| Total costs and expenses | 168,816 | 155,086 | ||
| Income (loss) from operations | 125,466 | 24,192 | ||
| Interest income | 3,681 | 2,092 | ||
| Interest expense | 7,320 | 7,918 | ||
| Income (loss) before income taxes | 121,827 | 18,366 | ||
| (benefit from) provision for income taxes | -245,197 | 881 | ||
| Net income (loss) | 367,024 | 17,485 | ||
| Basic EPS | 20.4 | 0.99 | ||
| Diluted EPS | 19.48 | 0.99 | ||
| Basic Average Shares | 17,987,000 | 17,579,000 | ||
| Diluted Average Shares | 18,840,000 | 17,687,000 | ||
RIGEL PHARMACEUTICALS INC (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL)